News
Governor Phil Murphy and ABHI announce UK health tech trade delegation to New Jersey in 2025
New Jersey Governor Phil Murphy participated in a roundtable discussion with the Association of British HealthTech Industries (ABHI) and its member companies as part of the Choose New Jersey governor-led economic mission to the United Kingdom.
The visit aimed to strengthen New Jersey’s ties with British partners, with a focus on advancing collaboration in the life sciences and HealthTech sectors, key industries for both economies.
The participation in the roundtable discussion builds on a successful September visit to New Jersey by a cohort from ABHI.
During the roundtable, Governor Murphy engaged with UK HealthTech companies and clinical leaders to explore synergies and growth opportunities within this high-potential sector.
ABHI, the UK’s leading HealthTech trade organisation, was instrumental in these discussions through its US Accelerator program, which supports UK HealthTech companies entering and scaling in the US market.
Governor Murphy said: “New Jersey is committed to fostering global partnerships that drive innovation and economic growth.
“Collaborating with ABHI and UK HealthTech leaders presents a unique opportunity to strengthen our state’s leadership in Life Sciences and HealthTech.
“Together, we’re building a transatlantic pipeline of talent, technology, and ideas that will fuel advancements in healthcare and benefit communities on both sides of the Atlantic.”
The September cohort’s visit to New Jersey laid a strong foundation for this partnership, with engagements across New Jersey’s leading healthcare and research institutions, including Liberty Science Center’s SciTech Scity, Hackensack Meridian Health, Rutgers University, and Rowan University.
These meetings, alongside discussions with leaders from New Jersey’s life sciences, healthcare, and academic sectors, helped shape a plan for ABHI to lead an economic delegation visit to New Jersey in April 2025.
This milestone highlights the growing collaboration between the UK and New Jersey, creating a vital platform for HealthTech companies to forge partnerships that drive innovation, economic growth, and advancements in healthcare for both regions.
“The collaboration between the UK and New Jersey is only beginning,” said Paul Benton, Managing Director, International at ABHI.
“With our U.S. Accelerator planning a delegation to New Jersey in 2025, this is a fantastic opportunity for UK business leaders to foster closer working relationships that benefit the health and wealth of those in both markets.”
The UK roundtable included prominent clinical leaders from across London, such as UCL Partners, Imperial College London, Barts Health NHS Trust, and the Howard de Walden Estate, which manages the Harley Street Health District.
Mark Kildea, Chief Executive of The Howard de Walden Estate, noted that “London has amazing healthcare capabilities and it is important that key stakeholders examine how they can improve patient care and outcomes.
“Investment, trade, and the sharing of best practices are critical in this regard, and so it is with great pleasure that we collaborate with our friends in New Jersey to improve healthcare for all parties.”
New Jersey’s life sciences sector is a major economic driver, employing over 105,000 people across pharmaceuticals, biotechnology, and medical device manufacturing as of 2020.
“New Jersey is home to approximately 4,300 life sciences establishments and a total of 113 hospitals, including specialty hospitals. Among these, there are 72 acute care hospitals.
“New Jersey’s partnership with ABHI is a testament to our commitment to driving innovation and expanding our life sciences sector,” said Wes Mathews, President & CEO of Choose New Jersey.
“With each engagement, from the September cohort’s visit to today’s roundtable, we’re strengthening New Jersey’s ties with UK HealthTech leaders and creating new avenues for collaboration.
“We look forward to welcoming ABHI’s trade delegation to New Jersey in 2025 and building on this momentum to bring new opportunities and advancements to both markets.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







2 Comments